Trial Profile

A Phase 1 Study of LY3200882 in Patients With Solid Tumors

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 09 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs LY 3200882 (Primary) ; Cisplatin; Gemcitabine; Paclitaxel
Indications Glioma; Head and neck cancer; Pancreatic cancer; Solid tumours; Squamous cell cancer
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors Eli Lilly and Company

Most Recent Events

26 Jun 2024 Planned End Date changed from 1 Aug 2024 to 1 Aug 2025.
20 Oct 2023 Planned End Date changed from 1 Aug 2023 to 1 Aug 2024.
19 Sep 2022 Planned End Date changed from 30 Dec 2022 to 1 Aug 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com